Filing Flows › Comparisons › SCNX vs TOVX
Scienture Holdings vs Theriva Biologics: SCNX and TOVX compared
Scienture Holdings is the larger company: $344K of revenue in its latest quarter (Q2 2026) against $300K for Theriva Biologics (Q1 2026). Theriva Biologics is more profitable, with an operating margin of -709.0% against -785.6%.
Where the money goes: SCNX and TOVX
Scienture Holdings (SCNX) · Q2 2026
Scienture Holdings, Q2 2026: revenue $344K, operating margin -785.6%, net loss $2.8M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Theriva Biologics (TOVX) · Q1 2026
Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%, net loss $2.0M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
| Scienture Holdings (SCNX) | Theriva Biologics (TOVX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2026 |
| Revenue | $344K | $300K |
| Operating margin | -785.6% | -709.0% |
| Net earnings | −$2.8M | −$2.0M |
| Net margin | -821.3% | -681.3% |
| Operating cash flow | −$3.1M | −$2.5M |
Questions
Which is bigger, Scienture Holdings or Theriva Biologics?
Scienture Holdings is the larger company: $344K of revenue in its latest quarter (Q2 2026) against $300K for Theriva Biologics (Q1 2026).
Is Scienture Holdings or Theriva Biologics growing faster?
Theriva Biologics is more profitable, with an operating margin of -709.0% against -785.6%.
More: Scienture Holdings earnings · how Scienture Holdings makes money · Theriva Biologics earnings · how Theriva Biologics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed May 5, 2026). Fiscal quarters can end on different dates. Not investment advice.